|
[1]
|
中华医学会风湿病学分会.系统性红斑狼疮诊断及治疗指南[J].中华风湿病学杂志, 2010, 14: 342-346. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfsbx98201005016 |
|
[2]
|
Rahman A, Isenberg DA. Systemic lupus erythematosus[J]. N Engl J Med, 2008, 358: 929-939. doi: 10.1056/NEJMra071297 |
|
[3]
|
Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus[J].Am J Med, 1976, 60: 221-225. doi: 10.1016/0002-9343(76)90431-9 |
|
[4]
|
Hansson GK, Hermansson A. The immune system in atherosclerosis [J]. Nat Immunol, 2011, 12: 204-212. |
|
[5]
|
Hafiane A1, Kellett S, Genest J. Treatment options for low high-density lipoproteins[J]. CurrOpinEndocrinol Diabetes Obe, 2014, 21:134-139. |
|
[6]
|
Karlsson H, Leanderson P, Tagesson C, et al. Lipoproteomics Ⅱ: Mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry [J]. Proteomics, 2005, 5:1431-1445. doi: 10.1002/pmic.200401010 |
|
[7]
|
Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL [J]. J Clin Invest, 2007, 117: 746-756. doi: 10.1172/JCI26206 |
|
[8]
|
Birner-Gruenberger R, Schittmayer M, Holzer M, et al. Understanding high-density lipoprotein function in disease: recent advances in proteomics unravel the complexity of its composition and biology [J]. Prog Lipid Res, 2014, 56:36-46. doi: 10.1016/j.plipres.2014.07.003 |
|
[9]
|
Norata GD, Pirillo A, Ammirati E, et al. Emerging role of high density lipoproteins as a player in the immune system [J]. Atherosclerosis, 2012, 220: 11-21. doi: 10.1016/j.atherosclerosis.2011.06.045 |
|
[10]
|
Dietrich C, Volovyk ZN, Levi M, et al. Partitioning of Thy-1, GM1, and cross-linked phospholipid analogs into lipid rafts reconstituted in supported model membrane monolayers [J]. Proc Natl Acad Sci USA, 2001, 98: 10642-10647. doi: 10.1073/pnas.191168698 |
|
[11]
|
Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals [J]. Nature, 2010, 464: 1357-1361. doi: 10.1038/nature08938 |
|
[12]
|
Hai T, Wolford CC, Chang AY-S. ATF3, a Hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? [J]. Gene Exp, 2010, 15:1-11. doi: 10.3727/105221610X12819686555015 |
|
[13]
|
Suzuki M, Pritchard DK, Becker L, et al. High-density lipoprotein suppresses the type Ⅰ interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide [J]. Circulation, 2010, 122: 1919-1927. doi: 10.1161/CIRCULATIONAHA.110.961193 |
|
[14]
|
Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex [J]. J Clin Invest, 2013, 123: 3815-3828. doi: 10.1172/JCI67478 |
|
[15]
|
Murphy AJ, Bijl N, Yvan-Charvet L, et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis [J]. Nat Med, 2013, 19: 586-594. doi: 10.1038/nm.3150 |
|
[16]
|
Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti- and pro-apoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling [J]. Circulation, 2013, 127: 891-904. doi: 10.1161/CIRCULATIONAHA.112.108753 |
|
[17]
|
Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE: mechanisms and management [J]. Nat Rev Rheumatol, 2012, 8: 214-223. doi: 10.1038/nrrheum.2012.14 |
|
[18]
|
Ronda N, Favari E, Borghi MO, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus [J]. Ann Rheum Dis, 2014, 73: 609-615. doi: 10.1136/annrheumdis-2012-202914 |
|
[19]
|
Smith CK, Vivekanandan-Giri A, Tang C, et al. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus [J]. Arthritis Rheumatol, 2014, 66: 2532-2544. doi: 10.1002/art.38703 |
|
[20]
|
McMahon M, Skaggs BJ, Sahakian L, et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids [J]. Ann Rheum Dis, 2011, 70: 1619-1624. doi: 10.1136/ard.2010.142737 |
|
[21]
|
McMahon M, Skaggs BJ, Grossman JM, et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus [J]. Arthritis Rheumatol, 2014, 66: 130-139. doi: 10.1002/art.38204 |
|
[22]
|
Skaggs BJ, Hahn BH, SahakianL, et al. Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFR beta, chemotaxis and TNF alpha production [J]. Clin Immunol, 2010, 137: 147-156. doi: 10.1016/j.clim.2010.06.014 |
|
[23]
|
Hahn BH, Grossman J, Ansell BJ, et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis [J]. Arthritis Res Ther, 2008, 10: 213. doi: 10.1186/ar2471 |
|
[24]
|
Charakida M, Besler C, Batuca JR, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome [J]. JAMA, 2009, 302: 1210-1217. doi: 10.1001/jama.2009.1346 |
|
[25]
|
Srivastava R, Yu S, Parks BW, et al. Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice [J]. Arthritis Rheumatol, 2011, 63: 201-211. doi: 10.1002/art.27764 |
|
[26]
|
Tripi LM, Manzi S, Chen Q, et al. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus [J]. Arthritis Rheumatol, 2006, 54: 1928-1939. doi: 10.1002/art.21889 |
|
[27]
|
Marsillach J, Becker JO, Vaisar T, et al. Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis [J]. J Proteome Res, 2015, 14: 2046-2054. doi: 10.1021/pr5011586 |
|
[28]
|
Parra S, Vives G, Ferre R, et al. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients [J]. Atherosclerosis, 2012, 225: 224-230. doi: 10.1016/j.atherosclerosis.2012.08.029 |
|
[29]
|
Navab M, Anantharamaiah GM, Reddy ST, et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice [J]. Arterioscler Thromb Vasc Biol, 2005, 25: 1932-1937. doi: 10.1161/01.ATV.0000174589.70190.e2 |
|
[30]
|
Woo JM, Lin Z, Navab M, et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis [J]. Arthritis Res Ther, 2010, 12: R93. doi: 10.1186/ar3020 |
|
[31]
|
Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-Ⅰ and high-density lipoprotein cholesterol in vitro and in vivo [J]. J Am Coll Cardiol, 2010, 55: 2580-2589. doi: 10.1016/j.jacc.2010.02.035 |
|
[32]
|
Goswami B, Rajappa M, Singh B, et al. Inflammation and dyslipidaemia: a possible interplay between established risk factors in North Indian males with coronary artery disease [J]. Cardiovasc J Afr, 2010, 21: 103-108. |
|
[33]
|
Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-Ⅰ(Milano) mutant: the Limonesul Garda study[J]. Circulation, 2001, 103: 1949-1954. doi: 10.1161/01.CIR.103.15.1949 |
|
[34]
|
Ibanez B, Vilahur G, Cimmino G, et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-Ⅰ Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis [J]. J Am Coll Cardiol, 2008, 51: 1104-1109. doi: 10.1016/j.jacc.2007.09.071 |
|
[35]
|
Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial [J]. JAMA, 2007, 297: 1675-1682. doi: 10.1001/jama.297.15.jpc70004 |
|
[36]
|
Hovingh GK, Smits LP, Stefanutti C, et al. Effects of CER-001 on carotid atherosclerosis by 3TMRI in homozygous familial hypercholesterolaemia (HOFH): themodifying orphan disease evaluation (MODE) study [J]. Am Heart J, 2015, 169: 736-742. doi: 10.1016/j.ahj.2015.01.008 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
